CAS NO: | 137975-06-5 |
包装 | 价格(元) |
10 mM * 1 mL in DMSO | 电议 |
10mg | 电议 |
50mg | 电议 |
100mg | 电议 |
200mg | 电议 |
500mg | 电议 |
生物活性 | Mozavaptan (OPC-31260) is a benzazepine derivative and a potent, selective, competitive and orally activevasopressin V2receptorantagonist with anIC50of 14 nM. Mozavaptan shows ~85-fold selectivity forV2receptorover V1receptor (IC50of 1.2 μM), and can antagonize the antidiuretic action of arginine vasopressin (AVP) in vivo. Mozavaptan has the potential for hyponatremia, syndrome of inappropriate antidiuretic hormone (SIADH), and congestive heart failure treatment[1][2]. | ||||||||||||||||
IC50& Target | IC50: 14 nM (Vasopressin V2receptor); 1.2 μM (Vasopressin V1receptor)[1] | ||||||||||||||||
体外研究 (In Vitro) | Mozavaptan (OPC-31260) inhibits AVP binding to binding to rat liver (V1 receptor) and kidney (V2 receptor) plasma membranes in a competitive manner and that it is about 100 times more selective for V2 receptors. Kdvalue for [3H]-AVP in rat liver is 1.1 nM; in rat kidney is 1.38 nM. The Kdof [3H]-AVP is reduced significantly in both rat liver and kidney in the presence of Mozavaptan (Kdof 2.47 nM and 5.51 nM for V1 receptor at the doses of 0.3 μM and 1 μM.respectively; Kdof 2.4 nM and 4.03 nM for V2 receptor at the doses of 0.3 μM and 1 μM.respectively)[1]. | ||||||||||||||||
体内研究 (In Vivo) | Mozavaptan (OPC-31260; 1-30 mg/kg; oral administration; hydrated conscious rats) treatment dose-dependently increases urine flow and decreased urine osmolality[1].
| ||||||||||||||||
分子量 | 427.54 | ||||||||||||||||
性状 | Solid | ||||||||||||||||
Formula | C27H29N3O2 | ||||||||||||||||
CAS 号 | 137975-06-5 | ||||||||||||||||
中文名称 | 莫扎伐普坦 | ||||||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||
储存方式 |
| ||||||||||||||||
溶解性数据 | In Vitro: DMSO : 6.2 mg/mL(14.50 mM;Need warming) 配制储备液
* 请根据半岛bd体育手机客户端
在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的半岛bd体育手机客户端
失效。 |